Healthcare of Ontario Pension Plan Trust Fund Takes Position in Taysha Gene Therapies, Inc. $TSHA

Healthcare of Ontario Pension Plan Trust Fund bought a new stake in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 3,722,000 shares of the company’s stock, valued at approximately $20,471,000.

Several other large investors have also recently made changes to their positions in the business. Barclays PLC increased its position in shares of Taysha Gene Therapies by 7.6% during the 4th quarter. Barclays PLC now owns 5,539,001 shares of the company’s stock valued at $30,465,000 after purchasing an additional 390,889 shares during the last quarter. Affinity Asset Advisors LLC increased its position in shares of Taysha Gene Therapies by 10.0% during the 4th quarter. Affinity Asset Advisors LLC now owns 3,300,000 shares of the company’s stock valued at $18,150,000 after purchasing an additional 300,000 shares during the last quarter. Rafferty Asset Management LLC increased its position in shares of Taysha Gene Therapies by 43.8% during the 4th quarter. Rafferty Asset Management LLC now owns 344,784 shares of the company’s stock valued at $1,896,000 after purchasing an additional 104,999 shares during the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of Taysha Gene Therapies by 3.1% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,902,978 shares of the company’s stock valued at $10,466,000 after purchasing an additional 56,468 shares during the last quarter. Finally, State Street Corp increased its position in shares of Taysha Gene Therapies by 49.1% during the 4th quarter. State Street Corp now owns 10,790,084 shares of the company’s stock valued at $59,345,000 after purchasing an additional 3,553,619 shares during the last quarter. 77.70% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, insider Sukumar Nagendran sold 200,000 shares of Taysha Gene Therapies stock in a transaction dated Friday, April 10th. The stock was sold at an average price of $4.46, for a total value of $892,000.00. Following the completion of the sale, the insider owned 1,136,410 shares of the company’s stock, valued at approximately $5,068,388.60. This trade represents a 14.97% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 3.78% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the company. Truist Financial raised Taysha Gene Therapies to a “strong-buy” rating in a research report on Wednesday, March 25th. Wall Street Zen lowered Taysha Gene Therapies from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Needham & Company LLC raised their target price on Taysha Gene Therapies from $10.00 to $12.00 and gave the company a “buy” rating in a research report on Thursday, March 19th. Chardan Capital reaffirmed a “buy” rating and set a $12.00 target price on shares of Taysha Gene Therapies in a research report on Thursday, March 19th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Taysha Gene Therapies in a research report on Friday, March 27th. Two investment analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $11.64.

Taysha Gene Therapies Trading Up 4.6%

Shares of TSHA opened at $5.97 on Tuesday. The business has a 50-day moving average of $5.80 and a 200 day moving average of $5.19. Taysha Gene Therapies, Inc. has a fifty-two week low of $2.25 and a fifty-two week high of $7.30. The firm has a market cap of $1.72 billion, a P/E ratio of -15.71 and a beta of 1.19. The company has a debt-to-equity ratio of 0.23, a quick ratio of 14.04 and a current ratio of 14.04.

Taysha Gene Therapies (NASDAQ:TSHA) last announced its quarterly earnings data on Wednesday, May 6th. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.02). As a group, research analysts forecast that Taysha Gene Therapies, Inc. will post -0.5 EPS for the current year.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.